Egnyte Releases Quality Document Management Offering
Egnyte announced a new product for emerging life sciences companies to manage regulated documentation. Egnyte for Life Sciences Quality is a GxP-compliant product that digitizes the lifecycle of regulated documents, like standard operating procedures (SOPs) and training records. Egnyte for Life Sciences Quality is the third product in a growing lineup of offerings, following the release of Egnyte for Life Sciences in November 2020 and new review and approval workflows.
Egnyte for Life Sciences Quality enables Life Sciences companies to:
- Meet GxP & FDA 21 CFR Part 11
- Perform e-Signatures: sign off on documents, like SOPs and clinical trial protocols, in a compliant manner, without needing third-party plugins.
- Manage effective documents: as new versions are approved, Quality teams can define version numbers for new drafts, set expiry dates, and ensure only effective copies are available.
- Scale compliance processes quickly: built with best practices gleaned from 17,000 global customers, Egnyte for Life Sciences Quality implements and validates as it integrates with existing IT infrastructure.
- Support for multiple departments and use cases: designed with the ability to support training, continuity, and site readiness documentation.
For more information, click here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
